Edesa Biotech, Inc.
NASDAQ: EDSA0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Capital Market
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Pardeep Nijhawan
- Employees
- 16
- Headquarters
- Markham, Canada
- IPO year
- 2010
- Market cap
- $70.7M
- Website
- https://www.edesabiotech.com
Loading EDSA…
Loading profile data…Frequently asked questions about EDSA
What does Edesa Biotech, Inc. (EDSA) do?
Edesa Biotech, Inc. is a biopharmaceutical firm focused on discovering, developing, and commercializing clinical-stage treatments for inflammatory and immune system disorders where current medical options are inadequate. The company's key pipeline assets include EB05, a monoclonal antibody undergoing a Phase 3 clinical trial for acute respirator...
Where does EDSA trade?
Edesa Biotech, Inc. (EDSA) trades on the NASDAQ Capital Market.
What sector is EDSA in?
Edesa Biotech, Inc. (EDSA) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Edesa Biotech, Inc.?
Pardeep Nijhawan is the chief executive officer of Edesa Biotech, Inc. (EDSA).
Where is Edesa Biotech, Inc. headquartered?
Edesa Biotech, Inc. is headquartered in Canada.
Does EDSA pay a dividend?
Edesa Biotech, Inc. (EDSA) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did EDSA go public?
Edesa Biotech, Inc. (EDSA) completed its initial public offering in 2010.